# Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen

> **NCT01879319** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 164 (actual)

## Conditions studied

- Primary Hypercholesterolemia
- Mixed Dyslipidemia

## Interventions

- **BIOLOGICAL:** Evolocumab AMD
- **BIOLOGICAL:** Evolocumab AI/pen

## Key facts

- **NCT ID:** NCT01879319
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-11
- **Primary completion:** 2013-11-15
- **Final completion:** —
- **Target enrollment:** 164 (ACTUAL)
- **Last updated:** 2022-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01879319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01879319, "Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01879319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*